STOCK TITAN

Sera Prognostics, Inc. - SERA STOCK NEWS

Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.

Sera Prognostics, Inc. (NASDAQ: SERA) is a biotechnology company based in Salt Lake City, Utah, specializing in the development of innovative diagnostic tests for early prediction of preterm birth risk and other pregnancy complications. Sera's mission is to provide pivotal pregnancy information to improve maternal and neonatal health. The company's flagship product, the PreTRM® Test, offers a unique blood-based biomarker test that predicts the individualized risk of spontaneous premature delivery in asymptomatic singleton pregnancies, allowing for proactive clinical interventions.

Sera Prognostics leverages a proprietary platform integrating proteomics and bioinformatics to discover, develop, and commercialize predictive analytic products that address the unmet needs in women's health. The company is committed to enhancing prenatal care and has formed strategic partnerships, including collaboration with the Bill & Melinda Gates Foundation to make its technologies accessible in underserved regions worldwide.

As a private entity supported by a robust investor base, including renowned names like Domain Associates and InterWest Partners, Sera Prognostics has assembled an expert management team and board of directors with substantial experience in clinical development and women's healthcare diagnostics. Recent achievements include the company's addition to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes, reflecting its growing market presence.

Financially, Sera Prognostics reported a significant reduction in operating expenses in recent quarters, aligning its commercial strategy with current market dynamics. The company continues to focus on advancing its product pipeline, including the development of ambient whole blood collection methods to enhance lab efficiency and reduce costs. The overall strategic directives aim at broadening test adoption and improving health outcomes, ultimately reducing the healthcare costs associated with maternal and neonatal complications.

For the latest updates, financial results, and operational highlights, interested parties can access the company's investor relations page and register for upcoming conference calls.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA), focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information, will report its first-quarter fiscal 2023 financial results on May 10, 2023. The report will follow a conference call at 5:00 PM ET, where operational highlights and financial results will be discussed. The PreTRM® Test, developed by Sera, predicts preterm birth risk, allowing for early interventions and potentially reducing healthcare costs associated with complications. The firm emphasizes its commitment to improving pregnancy care and health outcomes for mothers and newborns, while navigating various risks related to its revenue reliance on the PreTRM Test and potential market competition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
Rhea-AI Summary

Sera Prognostics, focused on maternal and neonatal health, reported its financial results for Q4 and full year 2022.

Q4 revenue increased to $65,000, up from $26,000 in Q4 2021. Full-year 2022 revenue reached $268,000, compared to $82,000 in 2021. Total operating expenses decreased to $10.5 million in Q4, down from $12.6 million in Q4 2021; however, full-year expenses rose to $45.9 million, up from $35.5 million.

The net loss for Q4 was $9.7 million, improved from $12.5 million the previous year. The company ended 2022 with approximately $104 million in cash and equivalents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.77%
Tags
-
Rhea-AI Summary

Sera Prognostics, Inc. (NASDAQ: SERA) will report its fourth quarter and full year 2022 financial results on March 22, 2023, after market close. A conference call to discuss the results will follow at 5:00 p.m. Eastern Time. The company is dedicated to improving maternal and neonatal health with its innovative pregnancy biomarker solutions, including the PreTRM® Test that predicts preterm birth risk. Sera's operational focus aims to enhance pregnancy care and reduce healthcare costs associated with complications from preterm births, which carry significant financial burdens estimated at $25 billion annually in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
-
Rhea-AI Summary

Sera Prognostics, known as The Pregnancy Company (NASDAQ: SERA), announced its participation in two significant upcoming healthcare conferences: the Cowen Health Care Conference in Boston from March 6-8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference virtually from March 13-15, 2023. CEO Gregory C. Critchfield will provide updates on the company's progress, including its innovative PreTRM® Test, which aids in predicting preterm birth risk. Both conferences will feature live webcasts available on the company's investor page, ensuring accessible information for stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
conferences
Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA) announced positive top-line results from the AVERT PRETERM TRIAL, showcasing significant improvements in neonatal health outcomes and reduced hospitalization duration. The study involved 1,453 expectant mothers and demonstrated statistically significant reductions in severe neonatal morbidity and mortality. Both primary outcomes were met, affirming the effectiveness of the PreTRM® test-and-treat strategy. These results build upon previous studies and support ongoing trials, including the large PRIME study. The PreTRM® Test provides crucial risk assessments for spontaneous preterm birth, aiming to enhance outcomes for mothers and infants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
73.28%
Tags
none

FAQ

What is the current stock price of Sera Prognostics (SERA)?

The current stock price of Sera Prognostics (SERA) is $6.54 as of November 22, 2024.

What is the market cap of Sera Prognostics (SERA)?

The market cap of Sera Prognostics (SERA) is approximately 218.8M.

What is Sera Prognostics' main product?

The main product of Sera Prognostics is the PreTRM® Test, a blood-based biomarker test for predicting the risk of preterm birth.

Where is Sera Prognostics headquartered?

Sera Prognostics is headquartered in Salt Lake City, Utah.

What is the mission of Sera Prognostics?

Sera Prognostics aims to improve maternal and neonatal health by providing early, pivotal pregnancy information to doctors and patients.

Who are some of the major investors in Sera Prognostics?

Major investors include the Bill & Melinda Gates Foundation, Domain Associates, InterWest Partners, and more.

What recent financial milestone has Sera Prognostics achieved?

Sera Prognostics has been added to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes.

How does the PreTRM® Test work?

The PreTRM® Test measures proteins in the blood during weeks 18-20 of pregnancy to predict the risk of spontaneous preterm birth.

What are the benefits of the PreTRM® Test?

The PreTRM® Test allows for early, individualized risk assessment of preterm birth, enabling proactive healthcare interventions to improve outcomes.

What strategic partnerships does Sera Prognostics have?

Sera Prognostics collaborates with the Bill & Melinda Gates Foundation to make its diagnostic technologies accessible in underserved regions.

What are the company's future plans for expanding its product offerings?

Sera Prognostics plans to enhance its product pipeline with new diagnostic tests and ambient whole blood collection methods to increase efficiency and reduce costs.

What challenges does Sera Prognostics face?

Challenges include achieving broad scientific and market acceptance of the PreTRM® Test, potential competition, and securing third-party payer coverage and reimbursement.

Sera Prognostics, Inc.

Nasdaq:SERA

SERA Rankings

SERA Stock Data

218.83M
28.54M
11.99%
71.57%
3.09%
Medical Devices
Services-medical Laboratories
Link
United States of America
SALT LAKE CITY